UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 17, 2016
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
|
001-36370 |
|
59-3553710 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
14193 NW 119th Terrace Suite 10 Alachua, Florida |
|
|
|
32615 |
|
(Address of Principal Executive Offices) |
|
|
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (386) 462-2204
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.esults of Operations and Financial Condition
On August 17, 2016, our board of directors appointed Anne M. VanLent to serve on our board of directors as a class I director. Ms. VanLent’s term will expire at our annual meeting of stockholders for fiscal year 2017. Ms. VanLent was also appointed to serve as the chairperson of our audit committee.
A copy of our press release dated August 18, 2016 announcing the appointment of Ms. VanLent to our board of directors is attached as Exhibit 99.1 to this Current Report.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release dated August 18, 2016, entitled “AGTC Appoints Anne M. VanLent to its Board of Directors.” |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
APPLIED GENETIC TECHNOLOGIES CORPORATION |
|
|
|
|
|
|
|
|
Date: August 18, 2016 |
|
By: |
/s/ Lawrence E. Bullock |
|
|
|
|
|
|
Lawrence E. Bullock |
|
|
|
|
|
Chief Financial Officer |
3
|
Exhibit No. |
Description |
|
99.1 |
Press release dated August 18, 2016, entitled “AGTC Appoints Anne M. VanLent to its Board of Directors.” |
4